Goldman Sachs Group Inc. Sells 183,751 Shares of Cytek Biosciences, Inc. $CTKB

Goldman Sachs Group Inc. lowered its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) by 13.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,158,001 shares of the company’s stock after selling 183,751 shares during the period. Goldman Sachs Group Inc. owned about 0.91% of Cytek Biosciences worth $4,644,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Voya Investment Management LLC grew its holdings in shares of Cytek Biosciences by 101.9% during the 1st quarter. Voya Investment Management LLC now owns 80,266 shares of the company’s stock valued at $322,000 after purchasing an additional 40,517 shares during the last quarter. Strs Ohio bought a new position in shares of Cytek Biosciences during the 1st quarter valued at $105,000. Acadian Asset Management LLC bought a new position in shares of Cytek Biosciences during the 1st quarter valued at $162,000. Jane Street Group LLC grew its holdings in shares of Cytek Biosciences by 412.2% during the 1st quarter. Jane Street Group LLC now owns 344,169 shares of the company’s stock valued at $1,380,000 after purchasing an additional 276,972 shares during the last quarter. Finally, Caxton Associates LLP purchased a new position in shares of Cytek Biosciences in the first quarter worth $409,000. Institutional investors own 69.46% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley decreased their target price on shares of Cytek Biosciences from $9.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cytek Biosciences has an average rating of “Hold” and a consensus target price of $5.60.

Cytek Biosciences Stock Down 1.5%

NASDAQ:CTKB opened at $3.90 on Wednesday. The stock has a market cap of $496.16 million, a P/E ratio of -78.00 and a beta of 1.36. The firm’s fifty day simple moving average is $3.81 and its 200 day simple moving average is $3.63. Cytek Biosciences, Inc. has a twelve month low of $2.37 and a twelve month high of $7.63.

About Cytek Biosciences

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.